argenx reports full year 2019 financial results and provides fourth quarter business update

NEXT STORY
Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Australia triggering the first milestone payment related to Asia-Pacific
PREV STORY
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period

author_avatar
NASDAQ Market News

Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency

Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in ...

author_avatar
NASDAQ Market News

Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

author_avatar
NASDAQ Market News